PDF
Supplemental Statement – Recombinant Influenza Vaccines An ACS NACI Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022–2023
Organization: Public Health Agency of Canada (PHAC)Published: 2022
"The objective of this advisory committee supplemental statement is to review the available evidence on the efficacy, effectiveness, immunogenicity, and safety of Supemtek, and to provide guidance on its use among adults in Canada." - Supplemental Statement – Recombinant Influenza Vaccines An ACS NACI Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022–2023
Resource Group:
Implementation Tool
Product Type: Guide
Program Delivery and Evaluation
Guides
Clinics
Vaccine Preventable Diseases
Communicable Diseases
Influenza
Product Type: Guide
Category:
Program Planning and Delivery,Program Delivery and Evaluation,Guides,Clinics,Vaccine Preventable Diseases,Communicable Diseases,Influenza Program Planning and DeliveryProgram Delivery and Evaluation
Guides
Clinics
Vaccine Preventable Diseases
Communicable Diseases
Influenza
Audience:
Health Care Professional
Population: Children (All)
High Risk Children
Adolescents
High Risk Adults
Indigenous Populations
Pregnant and Breastfeeding People
Seniors
Healthcare Personnel
Region: National
Population: Children (All)
High Risk Children
Adolescents
High Risk Adults
Indigenous Populations
Pregnant and Breastfeeding People
Seniors
Healthcare Personnel
Region: National
Language:
English
LinkResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.